GlaxoSmithKline Consumer Healthcare reported a 20.42 per cent increase in net profit to ₹211.81 crore for the quarter ended March 31, 2018, compared with ₹175.88 crore in the corresponding quarter in the previous fiscal. Revenue from operations in the fourth quarter was, however, down 2.48 per cent to ₹1179.58 crore.
For the full year ended March 31, 2018 ( FY2017-18), the company posted a 6.61 per cent increase in net profit to ₹700.10 crore against ₹656.68 crore in the previous fiscal. Revenue from operations in the financial year 2017-18 was almost flat at ₹4377.05 crore compared with the previous fiscal.
“The board of directors recommended a dividend at the rate of ₹75 per equity share of ₹10 each for the year ended March 31, 2018,” the company said in a statement.
Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare, said: “I am very satisfied with the overall quarter performance specially on volume growth in our health drinks portfolio and the share gain achieved by our lead brand Horlicks…. With a strong government focus on nutrition, better than expected monsoons and an improved business environment, we are bullish about the coming quarters.”
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.